PMID- 30341767 OWN - NLM STAT- MEDLINE DCOM- 20200615 LR - 20210126 IS - 1527-3350 (Electronic) IS - 0270-9139 (Print) IS - 0270-9139 (Linking) VI - 69 IP - 6 DP - 2019 Jun TI - Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. PG - 2414-2426 LID - 10.1002/hep.30320 [doi] AB - To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on liraglutide, sitagliptin, or insulin glargine in this 26-week trial. The primary endpoint was the change in intrahepatic lipid (IHL) from baseline to week 26 as quantified by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF). Secondary endpoints included changes in abdominal adiposity (subcutaneous adipose tissue [SAT] and visceral adipose tissue [VAT]), glycated hemoglobin, and body weight from baseline to week 26. We analysed data from intent-to-treat population. MRI-PDFF, VAT, and weight decreased significantly with liraglutide (15.4% +/- 5.6% to 12.5% +/- 6.4%, P < 0.001; 171.4 +/- 27.8 to 150.5 +/- 30.8, P = 0.003; 86.6 +/- 12.9 kg to 82.9 +/- 11.1 kg, P = 0.005, respectively) and sitagliptin (15.5% +/- 5.6% to 11.7% +/- 5.0%, P = 0.001; 153.4 +/- 31.5 to 139.8 +/- 27.3, P = 0.027; 88.2 +/- 13.6 kg to 86.5 +/- 13.2 kg, P = 0.005, respectively). No significant change in MRI-PDFF, VAT, or body weight was observed with insulin glargine. SAT decreased significantly in the liraglutide group (239.9 +/- 69.0 to 211.3 +/- 76.1; P = 0.020) but not in the sitagliptin and insulin glargine groups. Changes from baseline in MRI-PDFF, VAT, and body weight were significantly greater with liraglutide than insulin glargine but did not differ significantly between liraglutide and sitagliptin. Conclusion: Combined with metformin, both liraglutide and sitagliptin, but not insulin glargine, reduced body weight, IHL, and VAT in addition to improving glycemic control in patients with T2DM and NAFLD. CI - (c) 2018 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of American Association for the Study of Liver Diseases. FAU - Yan, Jinhua AU - Yan J AD - The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, China. FAU - Yao, Bin AU - Yao B AD - The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, China. FAU - Kuang, Hongyu AU - Kuang H AD - The First Affiliated Hospital of Harbin Medical University, Harbin, China. FAU - Yang, Xubin AU - Yang X AD - The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, China. FAU - Huang, Qin AU - Huang Q AD - Changhai Hospital, Shanghai, China. FAU - Hong, Tianpei AU - Hong T AD - Peking University Third Hospital, Beijing, China. FAU - Li, Yushu AU - Li Y AD - The First Hospital of China Medical University, Shenyang, China. FAU - Dou, Jingtao AU - Dou J AD - Chinese PLA General Hospital, Beijing, China. FAU - Yang, Wenying AU - Yang W AD - CHINA-JAPAN Friendship Hospital, Beijing, China. FAU - Qin, Guijun AU - Qin G AD - The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. FAU - Yuan, Huijuan AU - Yuan H AD - Henan Provincial Peoples Hospital, Zhengzhou, China. FAU - Xiao, Xinhua AU - Xiao X AD - Peking Union Medical College Hospital, Beijing, China. FAU - Luo, Sihui AU - Luo S AD - The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, China. FAU - Shan, Zhongyan AU - Shan Z AD - The First Hospital of China Medical University, Shenyang, China. FAU - Deng, Hongrong AU - Deng H AD - The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, China. FAU - Tan, Ying AU - Tan Y AD - The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, China. FAU - Xu, Fen AU - Xu F AD - The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, China. FAU - Xu, Wen AU - Xu W AD - The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, China. FAU - Zeng, Longyi AU - Zeng L AD - The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, China. FAU - Kang, Zhuang AU - Kang Z AD - The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, China. FAU - Weng, Jianping AU - Weng J AUID- ORCID: 0000-0001-6392-1163 AD - The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, China. LA - eng GR - Novo Nordisk/International GR - 81770821/National Natural Science Foundation of China/International GR - 201610010175/Pearl River S&T Nova Program of Guangzhou/International GR - 2016TQ03R590/Guangdong High-Level Talents Special Support Program/International PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20190222 PL - United States TA - Hepatology JT - Hepatology (Baltimore, Md.) JID - 8302946 RN - 0 (Blood Glucose) RN - 0 (Hypoglycemic Agents) RN - 2ZM8CX04RZ (Insulin Glargine) RN - 839I73S42A (Liraglutide) RN - 9100L32L2N (Metformin) RN - TS63EW8X6F (Sitagliptin Phosphate) SB - IM CIN - Hepatology. 2019 May;69(5):2304-2305. PMID: 30729549 CIN - Hepatology. 2019 May;69(5):2303-2304. PMID: 30734333 CIN - Hepatology. 2019 Jun;69(6):2318-2322. PMID: 31006135 CIN - Hepatology. 2020 Mar;71(3):1128. PMID: 31610029 CIN - Hepatology. 2020 Mar;71(3):1129. PMID: 31613385 MH - Adult MH - Aged MH - Blood Glucose/drug effects MH - Body Weight/drug effects MH - Comorbidity MH - Diabetes Mellitus, Type 2/diagnosis/*drug therapy/epidemiology MH - Dose-Response Relationship, Drug MH - Drug Administration Schedule MH - Female MH - Humans MH - Hypoglycemic Agents/therapeutic use MH - Insulin Glargine/*therapeutic use MH - Linear Models MH - Lipid Metabolism/drug effects MH - Liraglutide/*therapeutic use MH - Male MH - Metformin/*therapeutic use MH - Middle Aged MH - Multivariate Analysis MH - Non-alcoholic Fatty Liver Disease/diagnosis/*drug therapy/epidemiology MH - Prognosis MH - Prospective Studies MH - Sitagliptin Phosphate/*therapeutic use MH - Treatment Outcome PMC - PMC6594101 EDAT- 2018/10/21 06:00 MHDA- 2020/06/17 06:00 PMCR- 2019/06/26 CRDT- 2018/10/21 06:00 PHST- 2018/05/31 00:00 [received] PHST- 2018/10/15 00:00 [accepted] PHST- 2018/10/21 06:00 [pubmed] PHST- 2020/06/17 06:00 [medline] PHST- 2018/10/21 06:00 [entrez] PHST- 2019/06/26 00:00 [pmc-release] AID - HEP30320 [pii] AID - 10.1002/hep.30320 [doi] PST - ppublish SO - Hepatology. 2019 Jun;69(6):2414-2426. doi: 10.1002/hep.30320. Epub 2019 Feb 22.